Author: Zacks Small Cap Research

123455530 / 548 POSTS
By Brian Marckx, CFAOTC:SMLRREAD THE FULL SMLR RESEARCH REPORTQ2 2019 Results: Huge Beat to Our Numbers. Record Revenue, Income, EPS and Cash Flow. Moving PT to $55…Semler (OTC:SMLR) reported financial results for their second quarter ending June 30t ...
By Lisa ThompsonNASDAQ:ABDCREAD THE FULL ABDC RESEARCH REPORTNew management at Alcentra (NASDAQ:ABDC) has made significant progress revamping the portfolio and stabilizing NAV. The company was even able to pay a special $0.15 dividend this quarter. F ...
By Ian Gilson, PhD, CFANASDAQ:UHALREAD THE FULL UHAL RESEARCH REPORTAMERCO (NASDAQ:UHAL) reported its first fiscal quarter results on Aug. 7 followed by a conference call the following morning.Truck rental and Moving and Storage revenue were very clo ...
By Brian Marckx, CFANASDAQ:BLPHNASDAQ:MNKREAD THE FULL BLPH RESEARCH REPORTBrian Marckx, CFA, Senior Med-Tech Analyst with Zacks Small-Cap Research has initiated coverage of Bellerophon Therapeutics, Inc (BLPH) with a $3.25/share price target. See li ...
By John Vandermosten, CFANASDAQ:VVUSVivus (NASDAQ: VVUS) announced the approval of Qsymia in South Korea through the development efforts of partner Alvogen yesterday. The South Korean Ministry of Food and Drug Safety (MFDS) approved the drug as a saf ...
By Lisa ThompsonNASDAQ:OIIMREAD THE FULL OIIM RESEARCH REPORTO2Micro (NASDAQ:OIIM) revenues for Q2 came in above guidance at $14.3 million. This is a decrease of 6% compared with last year, but up 8% sequentially. Strength in HDR monitors and 8K TVs ...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdatePhase 2b Trial for VK2809 to Initiate 2H19Viking Therapeutics, Inc. (NASDAQ:VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the com ...
By David Bautz, PhDNASDAQ:SNGXREAD THE FULL SNGX RESEARCH REPORTSoligenix, Inc. (NASDAQ:SNGX) is a biopharmaceutical company currently conducting two pivotal Phase 3 clinical trials with its lead development compounds. • SGX301 is in a Phase 3 trial ...
By David Bautz, PhDNASDAQ:BVXVREAD THE FULL BVXV RESEARCH REPORT Financial UpdateOn July 16, 2019, BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced that the previously announced rights offering was fully subscribed and the company raised gross p ...
By Lisa ThompsonNASDAQ:CSSEREAD THE FULL CSSE RESEARCH REPORTManagement filed pro forma income statements for full year 2018 and the first quarter of 2019 and a pro forma balance sheet for March 31, 2019 with Crackle. Pro forma for 2018 the two would ...
123455530 / 548 POSTS